Analyses of NMDA-receptor co-agonists in serum among individuals with at-risk mental state for psychosis
Poster B96, Tuesday, October 9, 11:30 am - 1:00 pm, Essex Ballroom
Hiromi Tagata1, Naohisa Tsujino1,2, Mayu Onozato3, Naoyuki Katagiri1, Taiju Yamaguchi1, Takahiro nemoto1, Tkeshi Fukushima3, Masafumi Mizuno1; 1Toho University School of Medicine, 2Saiseikai Yokohamashi Tobu Hospital, 3Faculty of Pharmaceutical Sciences, Toho University
Aim: Individuals who meet the criteria for at-risk mental state for psychosis (ARMS) have a high risk of developing psychosis. However, useful predictors for the onset of psychosis in individuals with ARMS remains unclear. Therefore, the establishment of reliable biomarkers to predict development of psychosis in ARMS patients is urgently needed. Recently, N-methyl-D-aspartate (NMDA) receptor co-agonists abnormalities in serum of patients with schizophrenia have been reported. In this study, we examined NMDA-receptor co-agonists as biomarkers for the development of psychosis in individuals with ARMS. Method: We examined serum levels of NMDA-receptor co-agonists including glutamate, cysteine, glycine, γ-glutamylcysteine, glutathione, D-serine and L-serine in antipsychotic-naïve ARMS patients. We compared these levels with those in healthy controls. We also examined correlations between clinical scores and serum levels of NMDA-receptor co-agonists in individuals with ARMS. Results: A total of 24 individuals with ARMS and 42 healthy controls were enrolled in this study. The levels of γ-glutamylcysteine, glutathione and D-serine were significantly lower, but the glutamate level was higher in ARMS individuals compared to healthy controls. These results were equivalent to those of patients with schizophrenia. There were no correlations between clinical scores and serum levels of NMDA-receptor co-agonists in individuals with ARMS. Conclusion: The present study revealed that the levels of some NMDA-receptor co-agonists of individuals with ARMS were different from those of healthy controls, and was equivalent to those of patients with schizophrenia. The detection of abnormal levels of NMDA-receptor co-agonists may be useful for early diagnosis of psychosis.
Topic Area: Ultra High Risk / Prodromal Research